Merck cuts back on rotavirus vaccine commitment to West Africa: November’s industry headlines
Positive results for zoliflodacin, EMA approval for fexinidazole and Merck cuts rotavirus commitment – take a look a the month’s industry headlines.
Browsing: Drug Development
Could an insect-derived compound be a new class of antibiotics against Gram-negatives?
Researchers from the University of Zurich have discovered that thanatin, a compound produced naturally by the spined soldier bug, could target Gram-negative bacteria by preventing formation of the bacteria’s outer membrane – an unprecedented mechanism.
Overcoming intrinsic resistance in Pseudomonas aeruginosa using non-ribosome targeting tobramycin-based adjuvants
In this article, the authors discuss their research using non-ribosome targeting tobramycin-based adjuvants to overcome the intrinsic resistance observed in bacteria, Pseudomonas aeruginosa.
CRISPR-based antimicrobials: gene- and pathogen-focused applications
In recent years, researchers have discovered the potential of CRISPR as an antimicrobial. In this blog post we explain the recent advances made in this field and the different approaches by which CRISPR can be used as a new weapon in the battle against antimicrobial resistance.
Investigational antibiotic effective against drug-resistant UTIs in Phase II trial
A Phase II trial has demonstrated that a new investigational antibiotic, cefiderocol, is as effective as the current standard-of-care for treating complicated UTIs caused by multi-drug resistant bacteria.
FDA approves Xofluza™, the first single-dose oral medicine for influenza
Roche has announced the FDA approval of Xofluza™, the first and only single-dose oral medicine approved to treat flu.
Blocking toxin formation – a treatment for Gram-positive pathogens?
Small molecules that block bacterial toxin formation have shown promise against Gram-positive bacteria in mouse models.
The RESTORE-1 trial, results and real world repercussions – an interview with Keith Kaye
In this interview, we speak to to Keith Kaye, Principle Investigator of the RESTORE-1 trial assessing relebactam in combination with imipenem (IMI/REL), about the trial’s results and the implications these have for clinicians in ‘real world’ settings.
Phase III trial suggests meropenem–vaborbactam a valuable option for CRE infection
A Phase III study, TANGO II, has reported that meropenem–vaborbactam monotherapy for CRE infections was associated with improvement in clinical cure rates, lower nephrotoxicity and lower mortality versus best-available therapy.
Novartis and GARDP partner to accelerate the availability of antibiotics for children
GARDP and Novartis have announced a partnership hoping to accelerate the development and availability of generic antibiotics for children in LMICs.
